Andere Sprachen Alligator Bioscience AB

Aktien

A2AN1Z

SE0000767188

ATORX

Verzögert Nasdaq Stockholm Andere Börsenplätze 09:20:09 28.06.2024			% 5 Tage	% 1. Jan.
1,232 ^SEK	+1,99 %		+1,65 %	+78,52 %

26.06.	Alligator Bioscience gibt Ergebnisse der laufenden Optimize-1-Studie bekannt	CI
20.06.	Alligator Bioscience AB (publ) präsentiert positive Phase-2-Daten zu Mitazalimab bei Bauchspeicheldrüsenkrebs auf der ESMO GI 2024	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Alligator Bioscience : Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18 Month Analysis from Mitazalimab OPTIMIZE 1 Phase 2 Study in 1st Line Pancreatic Cancer	26.06.
Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer	26.06.
Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial	26.06.
Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025	25.06.
Alligator Bioscience AB to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024	20.06.
Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024	20.06.
Alligator Bioscience Names New CFO	14.06.
Alligator Bioscience Apppoints Johan Giléus as Chief Financial Officer	14.06.
BioStock: Alligator's mitazalimab data published in The Lancet Oncology	04.06.
Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology	03.06.
Alligator Bioscience Announces Publication of on Its Lead Drug Candidate Positive Phase 2 Data Mitazalimab in First Line Metastatic Pancreatic Cancer in the Lancet Oncology	03.06.
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	23.05.
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting	23.05.
US FDA Grants Investigational New Drug Clearance for Alligator Bioscience's Late-stage Gastric Cancer Treatment Trial	21.05.
Alligator Bioscience : Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer	21.05.
Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer	21.05.
Alligator Bioscience : Announces Publication Highlighting Potential of Next Generation CD40 Agonists in Peer Reviewed Medical Journal "Expert Opinion on Biological Therapy"	20.05.
Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal "Expert Opinion on Biological Therapy"	20.05.
Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer	14.05.
Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer	14.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alligator Bioscience AB

Aktien

A2AN1Z

SE0000767188

ATORX

Andere Sprachen

Filter